Baloxavir Marboxil?
?? ?Product Overview?
A novel single-dose oral antiviral targeting influenza A/B viruses. As a ?cap-dependent endonuclease inhibitor?, it blocks viral RNA replication, offering rapid symptom relief (within 48 hours) and reducing transmission risk?13. Widely used in ?influenza treatment and outbreak prevention? across hospitals, clinics, and community settings?25.

?Google Keywords?: Single-Dose Flu Treatment, Cap-Dependent Endonuclease Inhibitor, Influenza Antiviral Drug

?? ?Key Advantages?

?? ?1. Rapid & Convenient Therapy?

Single oral dose? achieves full therapeutic effect, eliminating multi-day dosing?.

Reduces symptom duration by 30–50%?vs. placebo in clinical trials?.

?? ?2. Precision Mechanism?

Targets viral cap-dependent endonuclease?, minimizing host cell toxicity?.

?? ?3. Global Quality Compliance?

Manufactured under USP/EP standards?, ensuring batch-to-batch consistency?.

?? ?Applications?

? ?Treatment?: Acute uncomplicated influenza in adults and adolescents?25.
? ?Prevention?: Post-exposure prophylaxis in high-risk populations?2.
? ?Public Health?: Outbreak control in closed settings (e.g., schools, nursing homes)?5.

?? ?Quality Certifications?

• ?USP-NF Monograph? compliant (purity ≥99.5%)?.
• ?EP 11.0? specifications validated via HPLC and mass spectrometry?.

?? ?Market Trends?
The global influenza antiviral market is projected to grow at ?6.8% CAGR (2025–2030)?, driven by rising pandemic preparedness and demand for fast-acting therapies?4. Baloxavir holds ?~25% market share? in next-gen influenza treatments due to its dosing advantage?24.

?Optimized for Search?: Influenza Antiviral API, USP-Grade Baloxavir, Single-Dose Antiviral Supplier

?Note?: Data sourced from clinical trials and pharmacopeial guidelines. Contact for COA and regulatory support.